Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3 [6] (Wadden et al., Nat Med , 2023))
Retatrutide at doses of 4 mg or higher significantly reduced fasting insulin (by 37% to 71%), HOMA2-IR (a measure of insulin resistance, reduced by 36% to 69%), and increased adiponectin (by 30% to 99%)
Eligibility criteria for NHS-funded GLP-1 treatment for weight management include: For semaglutide (Wegovy): BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) with at least one weight-related comorbidity For liraglutide (Saxenda): Similar BMI criteria as defined in NICE TA664 Evidence of previous weight management attempts through lifestyle modification Treatment must be initiated within specialist weight management services (Tier 3) Time-limited use as specified in the relevant NICE guidance The referral pathway typically involves: Initial GP consultation: Discuss weight concerns, document BMI and comorbidities, and review previous weight management efforts Tier 2/3 weight management services: Many areas require participation in structured lifestyle programmes before pharmacological intervention Specialist assessment: Referral to specialist weight management services for treatment initiation Ongoing monitoring: Regular review to assess response, tolerability, and continuation criteria Treatment continuation requires achieving the weight loss thresholds specified in the product-specific NICE guidance and SmPCs
Don't know what your GP was thinking of...might be worth re-visiting...see if you can get the 5mg dose u till your levels are raised sufficiently Presume you mean 400mcg and 800mcg rather than mg, in your reply
Glutathione, Ascorbic Acid, Vitamin E and Vitamin A provide antioxidant support
